Zimmer Biomet Names David DeMartino as Senior Vice President, Investor Relations
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) has announced the appointment of David DeMartino as Senior Vice President, Investor Relations, effective September 9, 2024. Reporting to CEO Ivan Tornos, DeMartino will lead the company's investor relations strategy and manage relationships with the investment community. With over 25 years of experience in healthcare, including asset management and equity research, DeMartino brings valuable industry knowledge to the role.
Prior to joining Zimmer Biomet, DeMartino served as Chief Strategy Officer at Nyxoah and held positions at DNB Asset Management, Velan Capital, Citadel, and Pura Vida Investments. His background also includes sell-side equity research at Deutsche Bank and Credit Suisse, as well as investment banking experience.
Zimmer Biomet Holdings, Inc. (NYSE e SIX: ZBH) ha annunciato la nomina di David DeMartino come Vice Presidente Senior, Relazioni con gli Investitori, con effetto dal 9 settembre 2024. Riportando al CEO Ivan Tornos, DeMartino guiderà la strategia di relazioni con gli investitori dell'azienda e gestirà i rapporti con la comunità degli investimenti. Con oltre 25 anni di esperienza nel settore sanitario, inclusi la gestione patrimoniale e la ricerca azionaria, DeMartino porta un prezioso know-how del settore nel suo ruolo.
Prima di unirsi a Zimmer Biomet, DeMartino ha ricoperto il ruolo di Chief Strategy Officer presso Nyxoah e ha occupato posizioni presso DNB Asset Management, Velan Capital, Citadel e Pura Vida Investments. Il suo background include anche ricerche azionarie sell-side presso Deutsche Bank e Credit Suisse, oltre a un'esperienza in investment banking.
Zimmer Biomet Holdings, Inc. (NYSE y SIX: ZBH) ha anunciado el nombramiento de David DeMartino como Vicepresidente Senior de Relaciones con Inversores, con efecto a partir del 9 de septiembre de 2024. Reportando al CEO Ivan Tornos, DeMartino liderará la estrategia de relaciones con inversores de la compañía y gestionará las relaciones con la comunidad de inversores. Con más de 25 años de experiencia en el sector de la salud, que incluye gestión de activos e investigación de acciones, DeMartino aporta un valioso conocimiento de la industria al puesto.
Antes de unirse a Zimmer Biomet, DeMartino fue Director de Estrategia en Nyxoah y ocupó puestos en DNB Asset Management, Velan Capital, Citadel y Pura Vida Investments. Su experiencia también incluye investigación de acciones en el lado de la venta en Deutsche Bank y Credit Suisse, así como experiencia en banca de inversión.
Zimmer Biomet Holdings, Inc. (NYSE 및 SIX: ZBH)는 David DeMartino를 2024년 9월 9일부터 투자자 관계 고위 부사장으로 임명한다고 발표했습니다. 그는 CEO Ivan Tornos에게 보고하며, 회사의 투자자 관계 전략을 이끌고 투자자 커뮤니티와의 관계를 관리할 것입니다. 25년 이상의 경험을 보유한 DeMartino는 자산 관리와 주식 연구를 포함한 의료 분야에서 소중한 산업 지식을 역할에 가져옵니다.
Zimmer Biomet에 합류하기 전에 DeMartino는 Nyxoah에서 최고 전략 책임자로 근무했으며, DNB Asset Management, Velan Capital, Citadel 및 Pura Vida Investments에서도 근무했습니다. 그의 경력에는 Deutsche Bank 및 Credit Suisse에서의 주식 연구와 투자 은행 경험도 포함됩니다.
Zimmer Biomet Holdings, Inc. (NYSE et SIX : ZBH) a annoncé la nomination de David DeMartino au poste de Vice-Président Senior des Relations Investisseurs, effective le 9 septembre 2024. Relevant du PDG Ivan Tornos, DeMartino dirigera la stratégie de relations investisseurs de l'entreprise et gérera les relations avec la communauté des investisseurs. Avec plus de 25 ans d'expérience dans le secteur de la santé, y compris la gestion d'actifs et la recherche en actions, DeMartino apporte une précieuse expertise sectorielle à ce poste.
Avant de rejoindre Zimmer Biomet, DeMartino a été Directeur de la Stratégie chez Nyxoah et a occupé des postes chez DNB Asset Management, Velan Capital, Citadel et Pura Vida Investments. Son parcours comprend également des recherches en actions côté vendeur chez Deutsche Bank et Credit Suisse, ainsi qu'une expérience en banque d'investissement.
Zimmer Biomet Holdings, Inc. (NYSE und SIX: ZBH) hat die Ernennung von David DeMartino zum Senior Vice President für Investor Relations bekannt gegeben, die am 9. September 2024 wirksam wird. Berichtend an CEO Ivan Tornos wird DeMartino die Investor-Relations-Strategie des Unternehmens leiten und die Beziehungen zur Investmentgemeinschaft verwalten. Mit über 25 Jahren Erfahrung im Gesundheitswesen, einschließlich Vermögensverwaltung und Aktienforschung, bringt DeMartino wertvolles Branchenwissen in diese Rolle ein.
Vor seinem Wechsel zu Zimmer Biomet war DeMartino Chief Strategy Officer bei Nyxoah und hatte Positionen bei DNB Asset Management, Velan Capital, Citadel und Pura Vida Investments inne. Zu seinem Hintergrund gehören auch Sell-Side-Aktienforschung bei Deutsche Bank und Credit Suisse sowie Erfahrungen im Investmentbanking.
- Appointment of experienced healthcare industry professional to lead investor relations
- New SVP brings diverse background in asset management, equity research, and investment banking
- Strategic hire to enhance relationships with the investment community
- None.
"We are excited to welcome David to Zimmer Biomet as our head of investor relations," said Mr. Tornos. "His impressive career achievements and extensive knowledge of the medtech industry, as both an investor and in equity research, make him the ideal candidate for this strategically important position. As we navigate an exciting and pivotal time for our Company, David will play a critical role in leading our IR initiatives and enhancing our positive relationships across the investment community."
Mr. DeMartino brings to Zimmer Biomet more than 25 years of experience in the healthcare industry, including asset management, equity research, and investment banking. Prior to joining ZB, he was Chief Strategy Officer at Nyxoah, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea. Mr. DeMartino was also a portfolio manager at DNB Asset Management and has held senior analysts positions at Velan Capital, Citadel and Pura Vida Investments, covering the medical devices, biotechnology and healthcare technology industries. In addition to investing in publicly traded companies at Pura Vida, he worked on private company investments. He spent several years in sell-side equity research, initially covering healthcare facilities at Deutsche Bank and then medical devices at Credit Suisse. He began his career with the Deutsche Bank Healthcare investment banking group. Mr. DeMartino earned a BA in Economics from
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.
Media | Investors |
Heather Zournas-Lubeski | Zach Weiner |
(445) 248-0577 | (908) 591-6955 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-names-david-demartino-as-senior-vice-president-investor-relations-302238707.html
SOURCE Zimmer Biomet Holdings, Inc.
FAQ
Who is the new Senior Vice President of Investor Relations at Zimmer Biomet (ZBH)?
What is David DeMartino's background before joining Zimmer Biomet (ZBH)?
When will David DeMartino start his new role at Zimmer Biomet (ZBH)?
Who will David DeMartino report to at Zimmer Biomet (ZBH)?
